Evidence map›Paper›PMID 41212886›Full record

ArticlePloS one2025

Dyslipidaemia and inflammation are risks for subclinical atherosclerotic vascular disease among chronic kidney failure patients in South Africa.

S O Oguntola, M O Hassan, R Duarte, C Dickens, T Dix-Peek, T Snyman, K Moodley, G Olorunfemi, A Vachiat, P Manga and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

S O OguntolaDivision of Nephrology, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-5442-6195
M O HassanDivision of Nephrology, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
R DuarteDepartment of Internal Medicine Laboratory, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
C DickensDepartment of Internal Medicine Laboratory, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
T Dix-PeekDepartment of Internal Medicine Laboratory, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
T SnymanDepartment of Chemical Pathology, University of the Witwatersrand, Johannesburg, South Africa.
K MoodleyDepartment of Internal Medicine Laboratory, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
G OlorunfemiDivision of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
A VachiatDepartment of Medicine, Division of Cardiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
P MangaDepartment of Medicine, Division of Cardiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
S NaickerDivision of Nephrology, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0002-7058-9725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with generalized inflammation. The presence of CKD-related (non-traditional) cardiovascular disease (CVD) risk factors such as inflammation, oxidative stress and uraemic toxins worsen the CVD. A distinct form of lipoprotein alteration known as uraemic dyslipidaemia, characterized by normal low-density lipoprotein (LDL), reduced high density lipoprotein (HDL) and elevated triglyceride and lipoprotein (a) has been described in CKD. The combination of all these factors increase the cardiovascular risk in CKD patients. We evaluated the relationship of lipoprotein and inflammatory biomarkers to atherosclerotic vascular disease (AsVD) among stage 3 CKD, end stage kidney disease (ESKD) patients on continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis (HD) and kidney transplant recipients (KTRs).

methodsThis was a cross-sectional study of 40 adult (18-65 years) non-diabetic stage 3 CKD patients, 40 CAPD and 40 HD patients, 41 KTRs and 41 age- and sex-matched healthy controls. Socio-demographic and cardiovascular risk factors were documented and serum samples were analysed for inflammatory and lipoprotein markers. Echocardiography was performed and carotid intima media thickness (CIMT) was measured in all participants.

resultsThe overall prevalence of AsVD was 52.8% in the study population, with the highest burden of inflammation present in CAPD patients. Significantly increased levels of hsCRP, pentraxin-3, Lp(a) and Lp-PLA2 were seen in CAPD, compared to controls. Older age, male gender, reduced high-density lipoprotein (HDL-C) and elevated Lp(a) levels were independently associated with AsVD.

conclusionThe burden of inflammation and lipoprotein abnormalities was greatest among end stage kidney disease (ESKD) patients and was the highest in CAPD patients. Lipoprotein(a) independently predicted AsVD.

Indexed as

AtherosclerosisDyslipidemiasInflammationKidney Failure, ChronicAdolescentAdultAgedBiomarkersCarotid Intima-Media ThicknessCross-Sectional StudiesFemaleHumansLipoprotein(a)MaleMiddle AgedRisk FactorsBiomarkersLipoprotein(a)

Identifiers

PMID41212886
PMCPMC12599917

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.